Header Logo

Connection

ERNEST HAWK to Anticarcinogenic Agents

Back to Details
This is a "connection" page, showing publications ERNEST HAWK has written about Anticarcinogenic Agents.
ERNEST HAWK
Connection Strength
2.328
Anticarcinogenic Agents
  1. Chemoprevention--history and general principles. Best Pract Res Clin Gastroenterol. 2011 Aug; 25(4-5):445-59.
    View in: PubMed
    Score: 0.326
  2. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):297-8.
    View in: PubMed
    Score: 0.208
  3. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003 Dec; 4(12):2193-204.
    View in: PubMed
    Score: 0.192
  4. Aspirin: still learning about the wonder drug. Gut. 2003 Nov; 52(11):1535-6.
    View in: PubMed
    Score: 0.191
  5. Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif. 2003; 21:759-89.
    View in: PubMed
    Score: 0.180
  6. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des. 2002; 8(12):1035-62.
    View in: PubMed
    Score: 0.168
  7. The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108.
    View in: PubMed
    Score: 0.167
  8. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92.
    View in: PubMed
    Score: 0.100
  9. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
    View in: PubMed
    Score: 0.082
  10. Modelling a dream: the molecular prevention of pancreatic cancer. Gut. 2010 May; 59(5):566-8.
    View in: PubMed
    Score: 0.075
  11. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
    View in: PubMed
    Score: 0.049
  12. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
    View in: PubMed
    Score: 0.047
  13. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003 Feb-Mar; 523-524:137-44.
    View in: PubMed
    Score: 0.045
  14. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol. 2002 Feb; 7(1):2-26.
    View in: PubMed
    Score: 0.042
  15. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):201-7.
    View in: PubMed
    Score: 0.040
  16. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ. 2001; 154:13-26.
    View in: PubMed
    Score: 0.039
  17. Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
    View in: PubMed
    Score: 0.038
  18. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000 Apr 01; 60(7):1864-70.
    View in: PubMed
    Score: 0.037
  19. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May; 8(5):467-83.
    View in: PubMed
    Score: 0.035
  20. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 06; 36(2):289-303.
    View in: PubMed
    Score: 0.031
  21. Progress in clinical chemoprevention. Semin Oncol. 1997 Apr; 24(2):241-52.
    View in: PubMed
    Score: 0.030
  22. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:79-85.
    View in: PubMed
    Score: 0.030
  23. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996 Jul; 17(7):1435-8.
    View in: PubMed
    Score: 0.029
  24. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ. 1996; (139):203-19.
    View in: PubMed
    Score: 0.028
  25. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14.
    View in: PubMed
    Score: 0.028
  26. New agents for cancer chemoprevention. J Cell Biochem Suppl. 1996; 26:1-28.
    View in: PubMed
    Score: 0.028
  27. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1996; 26:54-71.
    View in: PubMed
    Score: 0.028
  28. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl. 1995; 23:1-9.
    View in: PubMed
    Score: 0.026
  29. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology. 2004 Sep; 127(3):838-44.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.